ATAI
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show replicated clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by learning memory deficits no approved treatment in in predictive dose modeling phase concentration phase cognitive challenge phase a phase a a risked investigated excellent tolerability humans | ATAI
Company
Deck Type
Sector
Industry
Deck date
March 2023
Slide
10 of 31
Similar slides by ATAI
See diffirences between slides (animation)
Investor Presentation
April 2023
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show consistent clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by learning memory deficits no approved treatment in in predictive dose modeling phase concentration phase cognitive challenge phase a phase a a risked investigated good tolerability | ATAI
Investor Presentation
February 2023
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show replicated clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by episodic learning memory deficits no approved treatment in in predictive dose modeling phase concentration phase cognitive challenge phase a phase a a risked investigated excellent tolerability humans | ATAI
Investor Presentation
January 2023
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show replicated clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by episodic learning memory deficits no approved treatment in in predictive dose modeling phase concentration phase cognitive challenge phase a phase a a risked investigated excellent tolerability humans | ATAI
Investor Presentation
November 2022
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show replicated clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by episodic learning and memory deficits no approved treatment a risked excellent tolerability | ATAI
Related slides by other companies
Acast
Results
February 2022
quality first party data at scale | Acast
Equillium
Investor Presentation
February 2024
diversified pipeline of first in class immunology assets first class | Equillium
RayzeBio
IPO
September 2023
phase trial in first line combination treatment of | RayzeBio
Exscientia
Investor Presentation
March 2024
technology in action precision design of | Exscientia
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io